PMID- 32149330
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20220112
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 40
IP  - 4
DP  - 2020 Apr 30
TI  - LncRNA XIST promotes the progression of laryngeal squamous cell carcinoma via 
      sponging miR-125b-5p to modulate TRIB2.
LID - 10.1042/BSR20193172 [doi]
LID - BSR20193172
AB  - OBJECTIVE: X inactivate-specific transcript (XIST) is an attractive long 
      noncoding RNA (lncRNA) functioning as an indicator of various human tumors, 
      including laryngeal squamous cell carcinoma (LSCC). The present study was 
      conducted to explore a novel regulatory network of lncRNA XIST in LSCC cells. 
      MATERIALS AND METHODS: Quantitative real-time polymerase chain reaction (QRT-PCR) 
      was used to detect the expression levels of XIST, miR-125b-5p and TRIB2 in LSCC 
      cells and tissues. Cell proliferation, apoptosis, migration and invasion were 
      detected by Cell Counting Kit-8 (CCK-8), flow cytometry and Transwell assays, 
      separately. The relationship among XIST, miR-125b-5p and tribbles homolog 2 
      (TRIB2) was predicted by starBase v2.0 or TargetScan and confirmed by 
      Dual-luciferase reporter assay. The TRIB2 protein expression was quantified by 
      Western blot assay. Murine xenograft model was utilized to validate the role of 
      XIST in vivo. RESULTS: XIST was notably up-regulated in LSCC tissues and cells, 
      and the high level of XIST was associated with the low survival rate of LSCC 
      patients. XIST knockdown markedly repressed cell proliferation, migration and 
      invasion and promoted the apoptosis of LSCC cells and the effects were 
      antagonized by loss of miR-125b-5p. MiR-125b-5p was a target of XIST in LSCC 
      cells, and it could bind to TRIB2 as well. Moreover, XIST-loss-induced 
      down-regulation of TRIB2 could be significantly reversed by miR-125b-5p 
      knockdown. XIST promoted the growth of LSCC tumor in vivo. CONCLUSION: LncRNA 
      XIST promoted the malignance of LSCC cells partly through competitively binding 
      to miR-125b-5p, which in turn increased TRIB2 expression.
CI  - (c) 2020 The Author(s).
FAU - Liu, Chunxiu
AU  - Liu C
AD  - Department of Otolaryngology, Jining First People's Hospital of Shandong 
      Province, Jining, Shandong, China.
FAU - Lu, Zhenjun
AU  - Lu Z
AD  - Department of Otolaryngology, The Third People's Hospital, Qingdao, Shandong, 
      China.
FAU - Liu, Hui
AU  - Liu H
AD  - Department of Otolaryngology, Jining First People's Hospital of Shandong 
      Province, Jining, Shandong, China.
FAU - Zhuang, Shenfa
AU  - Zhuang S
AD  - Department of Otolaryngology, Jining First People's Hospital of Shandong 
      Province, Jining, Shandong, China.
FAU - Guo, Ping
AU  - Guo P
AD  - Department of Otolaryngology, Jining First People's Hospital of Shandong 
      Province, Jining, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Retracted Publication
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (MIRN125 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (XIST non-coding RNA)
RN  - EC 2.7.11.17 (Calcium-Calmodulin-Dependent Protein Kinases)
RN  - EC 2.7.11.17 (TRIB2 protein, human)
SB  - IM
RIN - Biosci Rep. 2022 Jan 28;42(1):. PMID: 35014669
MH  - Animals
MH  - Calcium-Calmodulin-Dependent Protein Kinases/*genetics
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/mortality/pathology/surgery
MH  - Laryngectomy
MH  - Larynx/pathology/surgery
MH  - Male
MH  - Mice
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Squamous Cell Carcinoma of Head and Neck/*genetics/mortality/pathology/surgery
MH  - Survival Rate
MH  - Treatment Outcome
MH  - Up-Regulation
MH  - Xenograft Model Antitumor Assays
PMC - PMC7146034
OTO - NOTNLM
OT  - LncRNA XIST
OT  - TRIB2
OT  - laryngeal squamous cell carcinoma
OT  - miR-125b-5p
COIS- The authors declare that there are no competing interests associated with the 
      manuscript. The present study was approved by the ethical review committee of 
      Jining First People's Hospital of Shandong Province. The analyzed data sets 
      generated during the present study are available from the corresponding author on 
      reasonable request.
EDAT- 2020/03/10 06:00
MHDA- 2021/03/30 06:00
PMCR- 2020/04/09
CRDT- 2020/03/10 06:00
PHST- 2019/09/06 00:00 [received]
PHST- 2019/12/19 00:00 [revised]
PHST- 2020/01/22 00:00 [accepted]
PHST- 2020/03/10 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/03/10 06:00 [entrez]
PHST- 2020/04/09 00:00 [pmc-release]
AID - 222318 [pii]
AID - BSR20193172 [pii]
AID - 10.1042/BSR20193172 [doi]
PST - ppublish
SO  - Biosci Rep. 2020 Apr 30;40(4):BSR20193172. doi: 10.1042/BSR20193172.